CClinicalTrials.gg
RecruitingNCT04446676Updated Mar 15, 2022

Impact of the Type of Stabilization in the Two-stage Knee Reimplantation on Reinfection - Prospective, Randomized Study.

An interventional study of stabilization with stem and stabilization with sleeve in Knee Infection, sponsored by Prof A Gruca Teaching Hospital. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-15.

Sponsored by Prof A Gruca Teaching Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 5 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Participants after first-stage of knee infection reimplantation will be assign to one of two groups: with stem vs. with sleeve. Investigators will check participants on clinical, laboratory and reinfection signs. The main hypothesis is that better mechanical stability of endoprosthesis with sleeves will support infection treatment.

Read the detailed description

All participants will be treated because of periprosthetic joint infection of the knee, after primary arthroplasty. All participants will be treated with two-stage protocol. In first stage debridement and spacer implantation will be performed. After 6-week antibiotics, when will be absent clinical or laboratory signs of reinfection, second stage will be performed. All participants upon fulfillment all inclusion and exclusion criteria will sign informed consent. With computer software patients will be randomized to one of two groups: with stem vs. with sleeve. After operation all patients will get target antibiotics for 3 weeks. Pre-operation and after on periodic controls will checked the Knee Society Score, The Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC), Visual Analogue Scale. After 2-year observation evaluation of reinfection rate will be performed in both groups.

02

Conditions studied

  • Knee Infection

Browse trials for

Keywords

  • knee arthroplasty
  • infection
  • two-stage
  • sleeve
  • stem
03

In context

Reinfection

45 studies on the registry are indexed under Reinfection; 7 are open to participants now.

This study's planned enrollment of 200 is above the median of 120 across 24 interventional studies indexed under Reinfection.

Browse Reinfection studies →

Lead sponsor

Prof A Gruca Teaching Hospital is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • second-stage of knee reimplantation
  • primary knee replacement in primary knee osteoarthritis
  • fulfillment of International Consensus Meeting 2018 infection criteria

Exclusion criteria

Exclusion Criteria:

  • intraoperative bone defects Anderson Orthopedic Research Institute score >II
  • autoimmune disease
  • diabetes
  • peripheral vascular disease
  • congenital or acquired immunodeficiencies
  • lack of pathogens after first-stage
  • multi-bacterial infection
  • multidirectional instability
  • lack of patient consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Stem stabilization

    Group of patients with stem endoprosthesis stabilization

    Device: stabilization with stem

  • Active comparator
    Sleeve stabilization

    Group of patients with sleeve endoprosthesis stabilization

    Device: stabilization with sleeve

Interventions

  • Devicestabilization with stem

    In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.

  • Devicestabilization with sleeve

    In both groups revision endoprosthesis of knee will be implanted with stem or sleeve stabilization.

06

What researchers measure

Primary outcomes

  1. Reinfection

    Rate of reinfection in both groups

    Time frame: 2 years

Secondary outcomes

  1. Loosening radiological signs

    Radiological evaluation of implant loosening with Modern Knee Society Radiographic Evaluation System

    Time frame: 2 years

Other outcomes

  1. Knee Society Score

    Clinical evaluation of patients after knee revision

    Time frame: 1 year

  2. The Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)

    Clinical evaluation of patients after knee revision

    Time frame: 1 year

  3. Visual Analogue Score

    Clinical evaluation of patients after knee revision

    Time frame: 1 year

  4. Alignment

    Radiological alignment of knee after operation in degrees

    Time frame: 6 weeks

  5. C-reactive protein

    After operation and at period controls (mg/l)

    Time frame: 1 year

  6. Erythrocyte sedimentation rate

    After operation and at period controls (mm/h)

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Gruca Teaching Hospital, Centre of Postgraduate Medical Centre
    Otwock, Mazowieckie 05-400, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol and Informed consent form will be shared

Supporting information: Study protocol, Icf

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04446676
Lead sponsor
Prof A Gruca Teaching Hospital
Responsible party
Bartosz Paweł (M.D., Ph.D., Prof A Gruca Teaching Hospital) — Principal investigator
First posted
Jun 25, 2020
Start date
Nov 17, 2020
Primary completion
Jul 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 15, 2022

Study contacts

Paweł Bartosz
Contact
pbartosz@vp.pl
+48 793629685
Paweł Bartosz
principal investigator · Prof. A. Gruca Teaching Hospital in Otwock

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion